Insulin pump therapy ... which has been supported by Novo Nordisk, Medtronic, Roche Diagnostics, Boehringer Ingelheim, and Lilly through institutional research grants. R.W.H. has not received ...

Martin de Bock receives funding from Novo Nordisk, Medtronic ... mean full patient access to training on how to use the insulin pumps will likely take years. Failing to address these issues ...

The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...

The insulin pump calibrates the amount of insulin she ... Three drug companies dominate the U.S. insulin market: Novo Nordisk, Eli Lilly and Sanofi. Last spring, Eli Lilly reported its drugs ...

and insulin pumps, which also make therapy more convenient, are already gaining in popularity. Novo Nordisk is investing heavily in another oral formulation: its next-generation GLP-1 analogue ...

For Novo Nordisk, a company still rooted in principles ... This formulation will be especially important for type 1 patients who use insulin pumps, a trend likely to develop in coming decades.

Australian Declan Irvine (Team Novo Nordisk) is a bit wary of the ... He explained that he had an insulin pump in a pocket that was connected to his continuous glucose monitor.